Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Research & Development (2016 - 2025)

Historic Research & Development for Marker Therapeutics (MRKR) over the last 10 years, with Q3 2025 value amounting to $2.3 million.

  • Marker Therapeutics' Research & Development fell 3242.01% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year increase of 3405.34%. This contributed to the annual value of $13.5 million for FY2024, which is 2928.98% up from last year.
  • As of Q3 2025, Marker Therapeutics' Research & Development stood at $2.3 million, which was down 3242.01% from $4.2 million recorded in Q2 2025.
  • In the past 5 years, Marker Therapeutics' Research & Development ranged from a high of $7.0 million in Q1 2022 and a low of $2.0 million during Q3 2023
  • Moreover, its 4-year median value for Research & Development was $2.9 million (2022), whereas its average is $3.3 million.
  • In the last 5 years, Marker Therapeutics' Research & Development crashed by 5194.33% in 2023 and then skyrocketed by 9432.82% in 2024.
  • Over the past 4 years, Marker Therapeutics' Research & Development (Quarter) stood at $2.2 million in 2022, then rose by 19.93% to $2.6 million in 2023, then surged by 94.33% to $5.1 million in 2024, then plummeted by 53.88% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $4.2 million for Q2 2025, and $3.1 million during Q1 2025.